Gedeon Richter Ltd. has prepared and tested bicyclic amine derivatives acting as GABA-A receptor α5 subunit (GABRA5) positive allosteric modulators.

Leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors have been detailed in a recent Merck Sharp & Dohme Corp. patent and reported to be useful for the treatment of Parkinson’s disease, among others.

The brain is plastic throughout life, but never more so than from birth to young adulthood. It increases its volume by developing dendrites and axons that connect neurons in to each other, forming new pathways to process the information that it will store. Those connections require maintenance. And if a connection is unsuccessful, better to delete it than to keep it. This is known as synaptic pruning and occurs from childhood to the age of 20. Now, a group of scientists from the University of Cambridge and Fudan University has described a neuropsychopathological (NP) factor that explains why inappropriate pruning in adolescence is related to mental health disorders.

A recent Hanmi Holdings Co. Ltd. patent describes 1-phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, rheumatoid arthritis and Crohn’s disease.

Humanwell Healthcare (Group) Co. Ltd. researchers have prepared and tested AP2-associated protein kinase 1 (AAK1) inhibitors that are reported to be useful for the treatment of bipolar disorder, pain, schizophrenia, Alzheimer’s and Parkinson’s disease.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented benzodiazepine derivatives acting as GABA(A) receptor subunit α2β2γ1 positive allosteric modulators and reported to be useful for the treatment of neurological disorders.